

letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of 4-Anilino-N-Phenethyl-4-Piperidine (ANPP) (8333), a basic class of controlled substance listed in schedule II.

The company plans to use this controlled substance in the manufacture of another controlled substance.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substance, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, **Federal Register Representative (ODL)**, 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than February 1, 2011.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 2010-30360 Filed 12-2-10; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Application**

Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 8, 2010, Agilent Technologies, 25200 Commercentre Drive, Lake Forest, California 92630-8810, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule II:

| Drug  | Schedule |
|---|----------|
| Phencyclidine (7471) .....                            | II       |
| 1-piperidinocyclohex-<br>anecarbonitrile (8603) ..... | II       |
| Benzoylcegonine (9180) .....                          | II       |

The company plans to manufacture small quantities of the listed controlled substances for use in diagnostic products.

Agilent Technologies submitted this application because, effective May 14, 2010, Varian, Inc., located at 25200 Commercentre Drive, Lake Forest, California 92630-8810, became a wholly-owned subsidiary of Agilent Technologies. Varian, Inc.'s legal existence as a corporation and as a DEA registrant as a bulk manufacturer will

eventually cease and Agilent Technologies will take over all of Varian Inc.'s activities with regard to controlled substances, requiring possession of a DEA registration as a bulk manufacturer issued to Agilent Technologies.

Presently, Agilent Technologies' activities with regard to controlled substances will be exactly the same as performed by Varian, Inc.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR § 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, **Federal Register Representative (ODL)**, 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than February 1, 2011.

Dated: November 18, 2010.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 2010-30358 Filed 12-2-10; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Registration**

By Notice dated May 28, 2010 and published in the **Federal Register** on June 8, 2010, (75 FR 32506), Boehringer Ingelheim Chemicals, Inc., 2820 N. Normandy Drive, Petersburg, Virginia 23805-9372, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances:

| Drug                              | Schedule |
|-----------------------------------|----------|
| Amphetamine (1100) .....          | II       |
| Lisdexamfetamine (1205) .....     | II       |
| Methylphenidate (1724) .....      | II       |
| Methadone (9250) .....            | II       |
| Methadone Intermediate (9254) ... | II       |

The company plans to manufacture the listed controlled substances in bulk for sale to its customers for formulation into finished pharmaceuticals.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Boehringer Ingelheim Chemicals, Inc. to manufacture the listed basic classes of controlled substances is consistent with

the public interest at this time. DEA has investigated Boehringer Ingelheim Chemicals, Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Dated: November 19, 2010.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 2010-30352 Filed 12-2-10; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF LABOR**

**Mine Safety and Health Administration**

**Petitions for Modification of Existing Mandatory Safety Standards**

**AGENCY:** Mine Safety and Health Administration (MSHA), Labor.

**ACTION:** Notice.

**SUMMARY:** Section 101(c) of the Federal Mine Safety and Health Act of 1977 and 30 CFR part 44 govern the application, processing, and disposition of petitions for modification. This notice is a summary of petitions for modification filed by the parties listed below to modify the application of existing mandatory safety standards published in Title 30 of the Code of Federal Regulations.

**DATES:** All comments on the petitions must be received by the Office of Standards, Regulations and Variances on or before January 3, 2011.

**ADDRESSES:** You may submit your comments, identified by "docket number" on the subject line, by any of the following methods:

1. *Electronic Mail:* [zzMSHA-comments@dol.gov](mailto:zzMSHA-comments@dol.gov). Include the docket number of the petition in the subject line of the message.

2. *Facsimile:* 1-202-693-9441.

3. *Regular Mail:* MSHA, Office of Standards, Regulations and Variances, 1100 Wilson Boulevard, Room 2350, Arlington, Virginia 22209-3939, Attention: Patricia W. Silvey, Director, Office of Standards, Regulations and Variances.